Emmanuel S Antonarakis Mbbch

List of Publications by Year
in descending order

333 papers	22,563 citations	22153 59 h-index	10734 138 g-index
340 all docs	340 docs citations	340 times ranked	24784 citing authors

#	Article	IF	Citations
1	Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 219-228.	3.9	12
2	Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy. Clinical Genitourinary Cancer, 2022, 20, 97-101.	1.9	14
3	Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer. Cancer Immunology, Immunotherapy, 2022, 71, 943-951.	4.2	9
4	Clinical and genomic features of SPOPâ€mutant prostate cancer. Prostate, 2022, 82, 260-268.	2.3	20
5	Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics. Prostate Cancer and Prostatic Diseases, 2022, 25, 713-719.	3.9	17
6	Bipolar androgen therapy (BAT): A patient's guide. Prostate, 2022, 82, 753-762.	2.3	6
7	Association of B7â€H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer. Cancer, 2022, 128, 2269-2280.	4.1	16
8	Clinical and pathological features associated with circulating tumor DNA content in realâ€world patients with metastatic prostate cancer. Prostate, 2022, 82, 867-875.	2.3	10
9	Extreme Responses to a Combination of DNA-Damaging Therapy and Immunotherapy in CDK12-Altered Metastatic Castration-Resistant Prostate Cancer: A Potential Therapeutic Vulnerability. Clinical Genitourinary Cancer, 2022, 20, 183-188.	1.9	3
10	Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss. European Urology Open Science, 2022, 41, 112-115.	0.4	4
11	PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers. JCO Precision Oncology, 2022, , .	3.0	15
12	Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies. JCO Precision Oncology, 2022, , .	3.0	10
13	Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. European Urology Oncology, 2021, 4, 447-455.	5.4	52
14	A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. European Urology, 2021, 79, 692-699.	1.9	49
15	Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 387-395.	0.8	19
16	CDK12 Deficiency and the Immune Microenvironment in Prostate Cancer. Clinical Cancer Research, 2021, 27, 380-382.	7.0	10
17	Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. Oncologist, 2021, 26, e270-e278.	3.7	33
18	Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis. Cancer Cell, 2021, 39, 68-82.e9.	16.8	66

#	Article	IF	Citations
19	Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. Modern Pathology, 2021, 34, 1185-1193.	5.5	61
20	Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research, 2021, 27, 1623-1630.	7.0	33
21	Detection of Early Progression with ¹⁸F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy. Journal of Nuclear Medicine, 2021, 62, 1270-1273.	5.0	6
22	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. European Urology, 2021, 80, 632-640.	1.9	61
23	Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigenâ€“Targeted ¹⁸F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. Journal of Nuclear Medicine, 2021, 62, 1430-1437.	5.0	24
24	Nivolumab plus ipilimumab, with or without enzalutamide, in ARâ€V7â€expressing metastatic castrationâ€resistant prostate cancer: A phaseâ€2 nonrandomized clinical trial. Prostate, 2021, 81, 326-338.	2.3	35
25	Streamlining Germline Genetic Testing in Prostate Cancer. European Urology Oncology, 2021, 4, 10-11.	5.4	1
26	Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2021, 39, 157-157.	1.6	0
27	Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. European Journal of Cancer, 2021, 144, 302-309.	2.8	29
28	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 134-143.	4.9	299
29	A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer. Clinical Cancer Research, 2021, 27, 3017-3027.	7.0	19
30	Reply to Salma Kaochar, Nicholas Mitsiadesâ€™ Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652â€“6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?. European Urology, 2021, 79, e94-e95.	1.9	0
31	Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer. Expert Opinion on Pharmacotherapy, 2021, 22, 1625-1632.	1.8	5
32	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. Journal of Clinical Oncology, 2021, 39, 1371-1382.	1.6	65
33	Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. European Journal of Cancer, 2021, 147, 74-83.	2.8	42
34	Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. Prostate, 2021, 81, 433-439.	2.3	29
35	Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Clinical Cancer Research, 2021, 27, 4077-4088.	7.0	21
36	AR Splicing Variants and Resistance to AR Targeting Agents. Cancers, 2021, 13, 2563.	3.7	27

#	Article	IF	Citations
37	Genomic profiles and clinical outcomes in primary versus secondary metastatic hormoneâ€sensitive prostate cancer. Prostate, 2021, 81, 572-579.	2.3	9
38	Mismatch repairâ€“deficient prostate cancer with parenchymal brain metastases treated with immune checkpoint blockade. Journal of Physical Education and Sports Management, 2021, 7, a006094.	1.2	4
39	TGM4: an immunogenic prostate-restricted antigen. , 2021, 9, e001649.		11
40	Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2021, 5, 1200-1220.	3.0	17
41	Targeting the spectrum of immune checkpoints in prostate cancer. Expert Review of Clinical Pharmacology, 2021, 14, 1253-1266.	3.1	13
42	Abstract 2404: Increased mitochondrial DNA copy number occurs during prostate cancer progression and in cancer precursor lesions across multiple organs. , 2021, , .		0
43	Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. European Urology Open Science, 2021, 30, 47-62.	0.4	2
44	Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. Prostate, 2021, 81, 1382-1389.	2.3	10
45	Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer. Cancer Research, 2021, 81, 5948-5962.	0.9	30
46	Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. European Urology Open Science, 2021, 34, 70-78.	0.4	3
47	New approaches to targeting the androgen receptor pathway in prostate cancer. Clinical Advances in Hematology and Oncology, 2021, 19, 228-240.	0.3	4
48	Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. European Urology, 2020, 77, 14-21.	1.9	51
49	A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 184-193.	3.9	32
50	Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer. Genes Chromosomes and Cancer, 2020, 59, 225-239.	2.8	18
51	Mathematical Modeling of Preclinical Alpha-Emitter Radiopharmaceutical Therapy. Cancer Research, 2020, 80, 868-876.	0.9	10
52	Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. Journal of Clinical Oncology, 2020, 38, 395-405.	1.6	450
53	Germline BLM mutations and metastatic prostate cancer. Prostate, 2020, 80, 235-237.	2.3	15
54	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. JCO Oncology Practice, 2020, 16, 811-819.	2.9	35

#	Article	IF	Citations
55	A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance. Nature Cancer, 2020, 1, 1082-1096.	13.2	49
56	Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene, 2020, 39, 6935-6949.	5.9	60
57	Genomic and Clinicopathologic Characterization ofATM-deficient Prostate Cancer. Clinical Cancer Research, 2020, 26, 4869-4881.	7.0	18
58	Neuroendocrine differentiation in usualâ€type prostatic adenocarcinoma: Molecular characterization and clinical significance. Prostate, 2020, 80, 1012-1023.	2.3	22
59	Reimagining Vaccines for Prostate Cancer: Back to the Future. Clinical Cancer Research, 2020, 26, 5056-5058.	7.0	3
60	BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?. Journal of Clinical Oncology, 2020, 38, 3735-3739.	1.6	38
61	PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date . Cancer Management and Research, 2020, Volume 12, 8105-8114.	1.9	58
62	When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials. European Urology Oncology, 2020, 3, 594-611.	5.4	63
63	Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2020, 4, 1285-1301.	3.0	42
64	Therapeutic targeting of the DNA damage response in prostate cancer. Current Opinion in Oncology, 2020, 32, 216-222.	2.4	11
65	The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer. Nature Communications, 2020, 11, 2689.	12.8	41
66	PARP inhibitors in prostate cancer: time to narrow patient selection?. Expert Review of Anticancer Therapy, 2020, 20, 523-526.	2.4	4
67	A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS). BMC Cancer, 2020, 20, 492.	2.6	16
68	Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations. Prostate Cancer and Prostatic Diseases, 2020, 23, 381-397.	3.9	34
69	Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. Journal of the National Cancer Institute, 2020, 112, 562-573.	6.3	45
70	Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines. Prostate, 2020, 80, 527-544.	2.3	34
71	Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer. European Journal of Cancer, 2020, 136, 16-24.	2.8	41
72	Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. European Urology, 2020, 78, 652-656.	1.9	64

#	Article	IF	Citations
73	Androgen receptor variant-driven prostate cancer II: advances in clinical investigation. Prostate Cancer and Prostatic Diseases, 2020, 23, 367-380.	3.9	22
74	Does sequencing order of antiandrogens in prostate cancer matter?. Nature Reviews Urology, 2020, 17, 197-198.	3.8	3
75	Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches. Cancer Treatment and Research Communications, 2020, 23, 100164.	1.7	22
76	Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer. Prostate, 2020, 80, 407-411.	2.3	24
77	Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer. JAMA Oncology, 2020, 6, 650.	7.1	696
78	CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO Precision Oncology, 2020, 4, 370-381.	3.0	138
79	T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer. Clinical Cancer Research, 2020, 26, 3182-3192.	7.0	64
80	TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?. Cancer Discovery, 2020, 10, 779-782.	9.4	329
81	Olaparib for DNA repair-deficient prostate cancer â€" one for all, or all for one?. Nature Reviews Clinical Oncology, 2020, 17, 455-456.	27.6	6
82	KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 5543-5543.	1.6	17
83	Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naÃ¯ve prostate cancer cells. Aging, 2020, 12, 17694-17712.	3.1	2
84	Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale. Translational Andrology and Urology, 2019, 8, S341-S345.	1.4	7
85	Genomic and clinical characterization of pulmonaryâ€only metastatic prostate cancer: A unique molecular subtype. Prostate, 2019, 79, 1572-1579.	2.3	23
86	Clinical implications of mismatch repair deficiency in prostate cancer. Future Oncology, 2019, 15, 2395-2411.	2.4	29
87	Clinical outcomes associated with pathogenic genomic instability mutations in prostate cancer: a retrospective analysis of US pharmacy and medical claims data. Journal of Medical Economics, 2019, 22, 1080-1087.	2.1	4
88	Reply to L. Dirix, B. De Laere et al, and A. Sharp et al. Journal of Clinical Oncology, 2019, 37, 2184-2186.	1.6	7
89	A pilot study of prostateâ€specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. Prostate, 2019, 79, 1597-1603.	2.3	18
90	Androgen Receptor Modulation Optimized for Responseâ€"Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7â€"expressing Metastatic Castration-resistant Prostate Cancer. European Urology, 2019, 76, 843-851.	1.9	36

#	Article	IF	Citations
91	Darolutamide For Castration-Resistant Prostate Cancer . OncoTargets and Therapy, 2019, Volume 12, 8769-8777.	2.0	24
92	Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer. Journal of Clinical Oncology, 2019, 37, 3507-3517.	1.6	43
93	Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. International Journal of Radiation Oncology Biology Physics, 2019, 105, 948-956.	0.8	37
94	PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. Clinical Genitourinary Cancer, 2019, 17, 470-475.e1.	1.9	26
95	Targeting lineage plasticity in prostate cancer. Lancet Oncology, The, 2019, 20, 1338-1340.	10.7	4
96	A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer. Oncologist, 2019, 24, 430-432.	3.7	19
97	A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). BMC Cancer, 2019, 19, 572.	2.6	3
98	Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clinical Genitourinary Cancer, 2019, 17, 275-282.e1.	1.9	42
99	Blocking the PD-1/PD-L1 axis in advanced prostate cancer: are we moving in the right direction?. Annals of Translational Medicine, 2019, 7, S7-S7.	1.7	20
100	Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COUâ€AAâ€302. Prostate, 2019, 79, 929-933.	2.3	3
101	Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. European Journal of Cancer, 2019, 114, 107-116.	2.8	42
102	Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. JCO Precision Oncology, 2019, 3, 1-23.	3.0	63
103	Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. Journal of Clinical Oncology, 2019, 37, 1120-1129.	1.6	267
104	Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2019, 3, 1-14.	3.0	23
105	Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. European Urology, 2019, 76, 452-458.	1.9	109
106	A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer. Investigational New Drugs, 2019, 37, 1052-1060.	2.6	11
107	Circulating tumor cell-based or tissue biopsy-based AR-V7 detection: which provides the greatest clinical utility?. Annals of Translational Medicine, 2019, 7, S354-S354.	1.7	4
108	CDK12 inactivation across solid tumors: an actionable genetic subtype. Oncoscience, 2019, 6, 312-316.	2.2	15

#	Article	IF	Citations
109	Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy. JCO Precision Oncology, 2019, 3, 1-13.	3.0	12
110	Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype. Oncologist, 2019, 24, 1526-1533.	3.7	39
111	Î±-Particleâ€“Emitter Radiopharmaceutical Therapy: Resistance Is Futile. Cancer Research, 2019, 79, 5479-5481.	0.9	13
112	Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations. JCO Precision Oncology, 2019, 3, 1-9.	3.0	47
113	Hormonal Therapy or Chemotherapy for Metastatic Prostate Cancer â€" Playing the Right CARD. New England Journal of Medicine, 2019, 381, 2564-2566.	27.0	5
114	Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage. Prostate Cancer and Prostatic Diseases, 2019, 22, 59-65.	3.9	67
115	Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. World Journal of Urology, 2019, 37, 2623-2629.	2.2	21
116	Favorable Response to Pembrolizumab in a Patient With Metastatic Castration-Resistant Prostate Cancer Progressing While Receiving Enzalutamide. Clinical Genitourinary Cancer, 2019, 17, e365-e368.	1.9	2
117	Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations. European Urology, 2019, 75, 378-382.	1.9	137
118	Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint. European Urology, 2019, 75, 929-937.	1.9	41
119	PARP inhibition â€" not all gene mutations are created equal. Nature Reviews Urology, 2019, 16, 4-6.	3.8	17
120	Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY. Clinical Cancer Research, 2019, 25, 1880-1888.	7.0	92
121	Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects. European Urology, 2019, 76, 170-176.	1.9	71
122	Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. European Urology, 2019, 75, 88-99.	1.9	333
123	Supraphysiological androgens suppress prostate cancer growth through androgen receptorâ€“mediated DNA damage. Journal of Clinical Investigation, 2019, 129, 4245-4260.	8.2	67
124	Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis.. Journal of Clinical Oncology, 2019, 37, 5045-5045.	1.6	12
125	Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199.. Journal of Clinical Oncology, 2019, 37, 216-216.	1.6	8
126	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 479-505.	4.9	943

#	Article	IF	Citations
127	Clinical Significance of AR-V567es in Prostate Cancerâ€"Response. Clinical Cancer Research, 2019, 25, 6010-6011.	7.0	1
128	Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors. Academic Radiology, 2018, 25, 1405-1414.	2.5	29
129	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Review of Clinical Pharmacology, 2018, 11, 475-486.	3.1	83
130	Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. European Urology, 2018, 74, 218-225.	1.9	140
131	Intraductal/ductal histology and lymphovascular invasion are associated with germline DNAâ€repair gene mutations in prostate cancer. Prostate, 2018, 78, 401-407.	2.3	105
132	The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. Prostate Cancer and Prostatic Diseases, 2018, 21, 306-318.	3.9	21
133	Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncology, 2018, 14, 907-917.	2.4	112
134	Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [18 F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation. Urology Case Reports, 2018, 17, 22-25.	0.3	7
135	CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer. Expert Review of Molecular Diagnostics, 2018, 18, 155-163.	3.1	51
136	p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2018, 21, 260-268.	3.9	48
137	PARP inhibitors for homologous recombination-deficient prostate cancer. Expert Opinion on Emerging Drugs, 2018, 23, 123-133.	2.4	24
138	Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. American Journal of Pathology, 2018, 188, 1478-1485.	3.8	119
139	A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. European Urology, 2018, 73, 156-165.	1.9	55
140	Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncology, The, 2018, 19, 76-86.	10.7	149
141	Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial. Clinical Cancer Research, 2018, 24, 306-315.	7.0	38
142	Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precision Oncology, 2018, 2018, 1-14.	3.0	14
143	Circulating Tumor Cell Eradication as an Intermediate Efficacy End Point for Metastatic Castration-Resistant Prostate Cancer: Is There Enough Evidence?. Journal of Clinical Oncology, 2018, 36, 525-527.	1.6	1
144	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. Journal of Clinical Oncology, 2018, 36, 991-999.	1.6	169

#	Article	IF	Citations
145	Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Medical Journal, 2018, 3, 104-104.	0.4	0
146	AR-V7 and treatment selection in advanced prostate cancer: are we there yet?. Precision Cancer Medicine, 2018, 1, 13-13.	1.8	8
147	Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget, 2018, 9, 28561-28571.	1.8	129
148	Germline Genetic Testing in Prostate Cancer â€“ Further Enrichment in Variant Histologies?. Oncoscience, 2018, 5, 62-64.	2.2	7
149	Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer. New England Journal of Medicine, 2018, 379, 1087-1089.	27.0	55
150	Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 6810-6815.	7.1	120
151	Detection of AR-V7 transcript with RNA in situ hybridization in human salivary duct cancer. Oral Oncology, 2018, 84, 134-136.	1.5	4
152	AR Signaling in Human Malignancies: Prostate Cancer and Beyond. Cancers, 2018, 10, 22.	3.7	15
153	Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Prostate Cancer and Prostatic Diseases, 2018, 21, 539-548.	3.9	99
154	Microsatellite instability in prostate cancer by PCR or next-generation sequencing. , 2018, 6, 29.		96
155	Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality?. Lancet Oncology, The, 2018, 19, 860-861.	10.7	7
156	Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. Clinical Cancer Research, 2018, 24, 4662-4671.	7.0	27
157	Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. European Urology, 2018, 73, 727-735.	1.9	55
158	KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2018, 36, 5007-5007.	1.6	72
159	Phase II trial of rucaparib (Without ADT) in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations (TRIUMPH).. Journal of Clinical Oncology, 2018, 36, TPS5095-TPS5095.	1.6	5
160	Comparison of healthcare resource use and treatment among prostate cancer patients with and without DNA damage repair gene mutations.. Journal of Clinical Oncology, 2018, 36, e17059-e17059.	1.6	0
161	Selective inhibitors of nuclear export: potential therapeutics for AR variant-expressing prostate cancer. Oncotarget, 2018, 9, 35797-35798.	1.8	0
162	Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. Clinical Cancer Research, 2017, 23, 3544-3551.	7.0	72

#	Article	IF	Citations
163	Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapyâ€naÃ¯ve castrationâ€resistant prostate cancer: The Kyotoâ€Baltimore collaboration. International Journal of Urology, 2017, 24, 441-448.	1.0	49
164	Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial. Clinical Cancer Research, 2017, 23, 2451-2459.	7.0	58
165	Treatment strategies for DNA repair-deficient prostate cancer. Expert Review of Clinical Pharmacology, 2017, 10, 889-898.	3.1	26
166	Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 Â® to Suppress Enzalutamide-resistant Prostate Cancer Progression. European Urology, 2017, 72, 835-844.	1.9	103
167	Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer. European Urology, 2017, 72, 323-325.	1.9	14
168	Germline DNA Repair Mutations and Response to Hormonal Therapy in Advanced Prostate Cancer. European Urology, 2017, 72, 43-44.	1.9	12
169	Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting. Journal of Molecular Diagnostics, 2017, 19, 115-125.	2.8	41
170	BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations. Expert Opinion on Investigational Drugs, 2017, 26, 1391-1397.	4.1	26
171	Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. Therapeutic Advances in Medical Oncology, 2017, 9, 565-573.	3.2	58
172	Reply to Julie Steinestel, Christof Bernemann, Andres J. Schrader, and Jochen K. Lennerz's Letter to the Editor re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. J Clin Oncol 2017;35:2149â€“56. AR-V7 Testing: What's in it for the Patient?. European Urology, 2017, 72, e170-e171.	1.9	1
173	The impact of statin use on the efficacy of abiraterone acetate in patients with castrationâ€resistant prostate cancer. Prostate, 2017, 77, 1303-1311.	2.3	19
174	MSH2 Loss in Primary Prostate Cancer. Clinical Cancer Research, 2017, 23, 6863-6874.	7.0	122
175	A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE). BMC Cancer, 2017, 17, 453.	2.6	83
176	Circulating Tumor Cells in Advanced Prostate Cancer: Time to Move from Prognostic to Predictive Ability. European Urology, 2017, 71, 172-173.	1.9	4
177	Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castrationâ€Resistant Prostate Cancer: A Retrospective Study. Prostate, 2017, 77, 33-40.	2.3	60
178	Do Patients With AR-V7â€“Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. European Urology, 2017, 71, 4-6.	1.9	24
179	Editorial Comment. Journal of Urology, 2017, 197, 142-142.	0.4	0
180	Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy. Oncotarget, 2017, 8, 104182-104192.	1.8	20

#	Article	IF	Citations
181	Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis. Prostate Cancer, 2017, 2017, 1-8.	0.6	15
182	Altering the Natural History of Oligometastatic Prostate Cancer With Local Therapies: Reality Versus Illusion. Journal of Oncology Practice, 2017, 13, 21-24.	2.5	6
183	Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. Journal of Clinical Oncology, 2017, 35, 2149-2156.	1.6	371
184	Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2017, 2017, 1-9.	3.0	42
185	Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-NaÂ¨ve, Metastatic, Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 3181-3188.	1.6	73
186	Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7+ metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 5005-5005.	1.6	23
187	Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 5035-5035.	1.6	19
188	Neoadjuvant randomized trial of degarelix (Deg) Â± cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP).. Journal of Clinical Oncology, 2017, 35, 5077-5077.	1.6	12
189	Detection fidelity of AR mutations in plasma derived cell-free DNA. Oncotarget, 2017, 8, 15651-15662.	1.8	20
190	Surrogate end points in early prostate cancer clinical states: ready for implementation?. Annals of Translational Medicine, 2017, 5, 502-502.	1.7	3
191	A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE).. Journal of Clinical Oncology, 2017, 35, TPS5094-TPS5094.	1.6	0
192	Prognostic and therapeutic implications of DNA repair gene mutations in advanced prostate cancer. Clinical Advances in Hematology and Oncology, 2017, 15, 785-795.	0.3	19
193	Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 131-141.	3.8	19
194	Galeterone for the treatment of advanced prostate cancer: the evidence to date. Drug Design, Development and Therapy, 2016, Volume 10, 2289-2297.	4.3	43
195	Medical hospitalizations in prostate cancer survivors. Medical Oncology, 2016, 33, 81.	2.5	2
196	Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 279-290.	2.3	16
197	Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. European Urology, 2016, 70, 963-970.	1.9	104
198	PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. Molecular Imaging and Biology, 2016, 18, 411-419.	2.6	202

#	Article	IF	Citations
199	Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer. Clinical Cancer Research, 2016, 22, 4651-4663.	7.0	34
200	Lumbosacral Plexus Involvement as the First Site of Metastatic Recurrence in a Patient With CTNNB1-Mutant Prostate Cancer. Clinical Genitourinary Cancer, 2016, 14, e417-e422.	1.9	0
201	Blood Based Detection of Androgen Receptor Splice Variants in Patients with Advanced Prostate Cancer. Journal of Urology, 2016, 196, 1606-1607.	0.4	5
202	<scp>Androgen receptor</scp> splice variant 7 in castrationâ€resistant prostate cancer: Clinical considerations. International Journal of Urology, 2016, 23, 646-653.	1.0	25
203	Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer. Oncologist, 2016, 21, 1427-1435.	3.7	60
204	Inherited HSD3B1 polymorphisms and hormonal therapy resistance. Lancet Oncology, The, 2016, 17, 1347-1349.	10.7	1
205	Bipolar Androgen Therapy for Men With Androgen Ablation NaÃ¯ve Prostate Cancer: Results From the Phase II BATMAN Study. Prostate, 2016, 76, 1218-1226.	2.3	63
206	Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide. Prostate, 2016, 76, 1484-1490.	2.3	29
207	Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology, 2016, 78, 1297-1304.	2.3	23
208	Sequencing Treatment for Castration-Resistant Prostate Cancer. Current Treatment Options in Oncology, 2016, 17, 64.	3.0	29
209	AR aberrations and resistance to abiraterone or enzalutamide. Nature Reviews Urology, 2016, 13, 697-698.	3.8	33
210	Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptorâ€directed therapies. Prostate, 2016, 76, 512-520.	2.3	19
211	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of Clinical Oncology, 2016, 34, 1402-1418.	1.6	1,089
212	Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer. Current Urology Reports, 2016, 17, 29.	2.2	22
213	docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study. Investigational New Drugs, 2016, 34, 112-118.	2.6	46
214	Comparison of Prostate-Specific Membrane Antigenâ€"Based ¹⁸F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-NaÃ¯ve and Castration-Resistant Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 46-53.	5.0	111
215	Co-targeting androgen receptor (AR) and DNA repair: A randomized ETS gene fusion-stratified trial of abiraterone + prednisone (Abi) +/- the PARP1 inhibitor veliparib for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) (NCI9012)â€"A University of Chicago phase II consortium trial.. Journal of Clinical Oncology, 2016, 34, 5010-5010.	1.6	11
216	AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): Expanded analysis of the Johns Hopkins cohort.. Journal of Clinical Oncology, 2016, 34, 5012-5012.	1.6	16

#	Article	IF	Citations
217	Updated results: A phase I/IIa randomized trial of radium-223 + docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases.. Journal of Clinical Oncology, 2016, 34, 5075-5075.	1.6	10
218	Patterns of metastatic disease progression after treatment with first-line enzalutamide or abiraterone in castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2016, 34, e16539-e16539.	1.6	1
219	E2809: Androgen receptor (AR) modulation by bicalutamide (Bic) and MK-2206 (MK) in men with rising PSA at high-risk of progression after local prostate cancer (PC) treatment.. Journal of Clinical Oncology, 2016, 34, 9-9.	1.6	2
220	Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, 131-141.	3.8	16
221	The STAMPEDE trial: paradigm-changing data through innovative trial design. Translational Cancer Research, 2016, 5, S485-S490.	1.0	15
222	Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. Clinical Medicine Insights: Oncology, 2016, 10, 1.	1.3	68
223	Sipuleucel-T (sip-T)â€“induced proliferative CD8+ T-cell responses to immunizing and secondary antigens.. Journal of Clinical Oncology, 2016, 34, 165-165.	1.6	1
224	Optimal sequencing of enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, 308-308.	1.6	0
225	Bipolar androgen therapy (BAT) in men with hormone sensitive (HS) prostate cancer (PC).. Journal of Clinical Oncology, 2016, 34, 236-236.	1.6	0
226	Contemporary treatment patterns and short-term outcomes in men with very high-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 103-103.	1.6	0
227	Cost-benefit analysis of AR-V7 testing in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) eligible for abiraterone (Abi) or enzalutamide (Enza).. Journal of Clinical Oncology, 2016, 34, 283-283.	1.6	0
228	A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination. Prostate, 2015, 75, 1518-1525.	2.3	88
229	Optimal sequencing of docetaxel and abiraterone in men with metastatic castrationâ€resistant prostate cancer. Prostate, 2015, 75, 1814-1820.	2.3	14
230	Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2015, 1, 582.	7.1	552
231	Does Degree of Androgen Suppression Matter in Hormone-Sensitive Prostate Cancer?. Journal of Clinical Oncology, 2015, 33, 1098-1100.	1.6	10
232	AR splice variant dimerizationâ€"clinical implications. Nature Reviews Urology, 2015, 12, 431-433.	3.8	10
233	The Effect of Therapeutic Anticoagulation on Overall Survival in Men Receiving First-Line Docetaxel Chemotherapy for Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2015, 13, 32-38.	1.9	15
234	Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?. Expert Review of Anticancer Therapy, 2015, 15, 143-145.	2.4	22

#	Article	IF	Citations
235	A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells. Cancer Immunology Research, 2015, 3, 1175-1184.	3.4	38
236	Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opinion on Pharmacotherapy, 2015, 16, 1521-1537.	1.8	50
237	Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study. Science Translational Medicine, 2015, 7, 269ra2.	12.4	205
238	Liquid biopsy: Clues on prostate cancer drug resistance. Science Translational Medicine, 2015, 7, 312fs45.	12.4	17
239	Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer. Current Treatment Options in Oncology, 2015, 16, 57.	3.0	30
240	Abstract CT134: Androgen receptor (AR) mutations in patients (pts) with castration-resistant prostate cancer (CRPC) with and without prior abiraterone acetate (AA) treatment. , 2015, , .		2
241	A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone.. Journal of Clinical Oncology, 2015, 33, TPS5072-TPS5072.	1.6	15
242	Clinical Implications of Hedgehog Pathway Signaling in Prostate Cancer. Cancers, 2015, 7, 1983-1993.	3.7	30
243	Resistance to Androgen-Pathway Drugs in Prostate Cancer. New England Journal of Medicine, 2014, 371, 2233-2234.	27.0	24
244	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine, 2014, 6, 224ra24.	12.4	3,665
245	The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer. Prostate Cancer and Prostatic Diseases, 2014, 17, 28-33.	3.9	18
246	Very-high-risk localized prostate cancer: definition and outcomes. Prostate Cancer and Prostatic Diseases, 2014, 17, 57-63.	3.9	91
247	Clinical activity of enzalutamide versus docetaxel in men with castrationâ€resistant prostate cancer progressing after abiraterone. Prostate, 2014, 74, 1278-1285.	2.3	84
248	The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer. European Urology, 2014, 66, 646-652.	1.9	126
249	Growth factor and signaling pathways and their relevance to prostate cancer therapeutics. Cancer and Metastasis Reviews, 2014, 33, 581-594.	5.9	27
250	Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone. Hormones and Cancer, 2014, 5, 265-273.	4.9	102
251	AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. New England Journal of Medicine, 2014, 371, 1028-1038.	27.0	2,233
252	Clinical activity of enzalutamide in Docetaxelâ€naÃ¯ve and Docetaxelâ€pretreated patients with metastatic castrationâ€resistant prostate cancer. Prostate, 2014, 74, 1560-1568.	2.3	36

#	Article	IF	Citations
253	Association of pretreatment neutrophilâ€toâ€lymphocyte ratio (<scp>NLR</scp>) and overall survival (<scp>OS</scp>) in patients with metastatic castrationâ€resistant prostate cancer (<scp>mCRPC</scp>) treated with firstâ€line docetaxel. BJU International, 2014, 114, E11-E17.	2.5	81
254	Castration-resistant prostate cancer: latest evidence and therapeutic implications. Therapeutic Advances in Medical Oncology, 2014, 6, 167-179.	3.2	67
255	High-Dose Itraconazole As a Noncastrating Therapy for a Patient With Biochemically Recurrent Prostate Cancer. Clinical Genitourinary Cancer, 2014, 12, e51-e53.	1.9	12
256	The effect of prior abiraterone (Abi) use on the activity of enzalutamide (Enza) in men with mCRPC.. Journal of Clinical Oncology, 2014, 32, 18-18.	1.6	28
257	Chemotherapy and its evolving role in the management of advanced prostate cancer. Asian Journal of Andrology, 2014, 16, 334.	1.6	19
258	Enzalutamide in chemo-naÃ¯ve castration-resistant prostate cancer: effective for most but not for all. Asian Journal of Andrology, 2014, 16, 807.	1.6	5
259	A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA. , 2014, 2, 21-32.		12
260	A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology, 2013, 71, 883-892.	2.3	59
261	Management of Patients with Biochemical Recurrence After Local Therapy for Prostate Cancer. Hematology/Oncology Clinics of North America, 2013, 27, 1205-1219.	2.2	30
262	A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naÃ¯ve prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 581-588.	1.6	57
263	Paraneoplastic Palmar Fasciitis and Polyarthritis Syndrome in a Patient With Advanced Prostate Cancer. Clinical Genitourinary Cancer, 2013, 11, e15-e23.	1.9	12
264	Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Annals of Oncology, 2013, 24, 2881-2886.	1.2	95
265	Molecularly Targeted Agents as Radiosensitizers in Cancer Therapyâ€"Focus on Prostate Cancer. International Journal of Molecular Sciences, 2013, 14, 14800-14832.	4.1	34
266	Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer. Oncologist, 2013, 18, 163-173.	3.7	145
267	Phase III Trials With Docetaxel-Based Combinations for Metastatic Castration-Resistant Prostate Cancer: Time to Learn From Past Experiences. Journal of Clinical Oncology, 2013, 31, 1709-1712.	1.6	65
268	Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer. Clinical Medicine Insights Urology, 2013, 7, CMU.S8337.	0.4	4
269	Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer. Core Evidence, 2013, 8, 27.	4.7	22
270	Tumorigenic potential of circulating prostate tumor cells. Oncotarget, 2013, 4, 413-421.	1.8	32

#	Article	IF	Citations
271	Phase II trial of single-agent ganetespib (STA-9090), a heat shock protein 90 (Hsp90) inhibitor in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel-based chemotherapy: Results of a Prostate Cancer Clinical Trials Consortium (PCCTC) study.. Journal of Clinical Oncology, 2013, 31, 5085-5085.	1.6	4
272	Association of metastasis-free survival (MFS) with overall survival (OS) in men with PSA-recurrent prostate cancer treated with deferred androgen-deprivation therapy.. Journal of Clinical Oncology, 2013, 31, 109-109.	1.6	2
273	Enzalutamide: The emperor of all anti-androgens. Translational Andrology and Urology, 2013, 2, 119-120.	1.4	8
274	Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clinical Advances in Hematology and Oncology, 2013, 11, 14-23.	0.3	119
275	Combining immunological and androgen-directed approaches. Current Opinion in Oncology, 2012, 24, 258-265.	2.4	23
276	Current status of immunological approaches for the treatment of prostate cancer. Current Opinion in Urology, 2012, 22, 197-202.	1.8	14
277	Sipuleucel-T for the treatment of metastatic prostate cancer. Human Vaccines and Immunotherapeutics, 2012, 8, 509-519.	3.3	16
278	Immunotherapy for Prostate Cancer Enters Its Golden Age. Clinical Medicine Insights: Oncology, 2012, 6, CMO.S7475.	1.3	6
279	Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Therapeutic Advances in Urology, 2012, 4, 167-178.	2.0	56
280	Flagellate erythema secondary to bleomycin. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 901-901.	0.5	2
281	Abiraterone acetate: a hat trick of clinical benefits. Lancet Oncology, The, 2012, 13, 1173-1174.	10.7	2
282	The Experience with CytotoxicÂChemotherapy inÂMetastatic Castration-Resistant Prostate Cancer. Urologic Clinics of North America, 2012, 39, 573-581.	1.8	4
283	Targeting angiogenesis for the treatment of prostate cancer. Expert Opinion on Therapeutic Targets, 2012, 16, 365-376.	3.4	32
284	Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. Cancer Letters, 2012, 323, 135-146.	7.2	88
285	Surgical Resection of Malignant Melanoma Metastatic to the Pancreas: Case Series and Review of Literature. Journal of Gastrointestinal Cancer, 2012, 43, 431-436.	1.3	21
286	Prostate angiosarcoma: a case report and literature review. Medical Oncology, 2012, 29, 2901-2903.	2.5	8
287	Use of androgen deprivation therapy in prostate cancer: indications and prevalence. Asian Journal of Andrology, 2012, 14, 177-186.	1.6	44
288	Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer. Asian Journal of Andrology, 2012, 14, 520-521.	1.6	10

#	Article	IF	Citations
289	Lenalidomide modulates ILâ€8 and antiâ€prostate antibody levels in men with biochemically recurrent prostate cancer. Prostate, 2012, 72, 487-498.	2.3	13
290	An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer, 2012, 118, 6063-6071.	4.1	91
291	The natural history of metastatic progression in men with prostateâ€specific antigen recurrence after radical prostatectomy: longâ€term followâ€up. BJU International, 2012, 109, 32-39.	2.5	221
292	Prostate angiosarcoma: is there any association with previous radiation therapy?. BJU International, 2012, 110, E819-25.	2.5	6
293	The effect of clinical trial participation versus nonâ€participation on overall survival in men receiving firstâ€line docetaxelâ€containing chemotherapy for metastatic castrationâ€resistant prostate cancer. BJU International, 2012, 110, E575-82.	2.5	28
294	Changes in PSA kinetics predict metastasisâ€free survival in men with PSAâ€recurrent prostate cancer treated with nonhormonal agents. Cancer, 2012, 118, 1533-1542.	4.1	47
295	Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. Cancer Chemotherapy and Pharmacology, 2012, 69, 763-771.	2.3	21
296	Treatment of Castration-Resistant Prostate Cancer. , 2012, , 2954-2971.e4.		3
297	Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer. Asian Journal of Andrology, 2012, 14, 655-655.	1.6	1
298	Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2011, 14, 192-205.	3.9	61
299	Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination. European Journal of Cancer, 2011, 47, 1955-1961.	2.8	111
300	Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2011, 14, 206-218.	3.9	25
301	Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Design, Development and Therapy, 2011, 5, 117.	4.3	111
302	Longâ€term overall survival and metastasisâ€free survival for men with prostateâ€specific antigenâ€recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. BJU International, 2011, 108, 378-385.	2.5	72
303	The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen Deprivation. Prostate, 2011, 71, 1608-1615.	2.3	25
304	The unfolding treatment landscape for men with castration-resistant prostate cancer. Clinical Investigation, 2011, 1, 1533-1544.	0.0	2
305	Expanding Treatment Options for Metastatic Prostate Cancer. New England Journal of Medicine, 2011, 364, 2055-2058.	27.0	80
306	Abiraterone acetate for prostate cancer: a new era of hormonal therapies. Asian Journal of Andrology, 2011, 13, 663-664.	1.6	3

#	Article	IF	Citations
307	Management of metastatic castration-resistant prostate cancer. European Urological Review, 2011, 6, 90-96.	0.0	1
308	Reply to P. Mathew. Journal of Clinical Oncology, 2010, 28, e198-e198.	1.6	0
309	Current status of immunological therapies for prostate cancer. Current Opinion in Urology, 2010, 20, 241-246.	1.8	45
310	Ruthenium-based chemotherapeutics: are they ready for prime time?. Cancer Chemotherapy and Pharmacology, 2010, 66, 1-9.	2.3	421
311	Update: Immunological Strategies for Prostate Cancer. Current Urology Reports, 2010, 11, 202-207.	2.2	30
312	Future Directions in Castrate-Resistant Prostate Cancer Therapy. Clinical Genitourinary Cancer, 2010, 8, 37-46.	1.9	10
313	Lenalidomide in Nonmetastatic Biochemically Relapsed Prostate Cancer: Results of a Phase I/II Double-Blinded, Randomized Study. Clinical Cancer Research, 2010, 16, 5269-5276.	7.0	44
314	Combining low-dose cyclophosphamide with GM-CSFâ€“secreting prostate cancer immunotherapy enhances antitumor immune effects. Expert Opinion on Investigational Drugs, 2010, 19, 311-314.	4.1	11
315	Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Letters, 2010, 291, 1-13.	7.2	78
316	Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?. Nature Clinical Practice Oncology, 2009, 6, 12-13.	4.3	13
317	Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men With Clinically Localized Prostate Cancer: Evaluation of Drug-Specific Biomarkers. Journal of Clinical Oncology, 2009, 27, 4986-4993.	1.6	57
318	Does short-term ADT before and during radiation therapy improve outcomes in locally advanced prostate cancer?. Nature Reviews Urology, 2008, 5, 480-481.	1.4	2
319	Beware of First Impressions. New England Journal of Medicine, 2008, 359, 628-634.	27.0	17
320	Rheumatoid Arthritis Masked by Docetaxel Chemotherapy in a Patient With Ovarian Carcinoma. Journal of Clinical Rheumatology, 2008, 14, 121.	0.9	4
321	Survival in Men With Nonmetastatic Prostate Cancer Treated With Hormone Therapy: A Quantitative Systematic Review. Journal of Clinical Oncology, 2007, 25, 4998-5008.	1.6	38
322	Not What It Seems. American Journal of Medicine, 2007, 120, 408-411.	1.5	0
323	A Cut Above. American Journal of Medicine, 2007, 120, 1031-1033.	1.5	5
324	Pemberton Sign. Mayo Clinic Proceedings, 2007, 82, 859.	3.0	5

#	Article	IF	Citations
325	Visual Vignette. Endocrine Practice, 2007, 13, 322.	2.1	0
326	Orientation of the stethoscope around the neck: A random phenomenon or an indicator of cerebral lateralisation? Cross-sectional survey. Laterality, 2006, 11, 287-293.	1.0	4
327	An Atypical Complication of Atypical Pneumonia. American Journal of Medicine, 2006, 119, 824-827.	1.5	17
328	Acquired Leukonychia Totalis. New England Journal of Medicine, 2006, 355, e2.	27.0	15
329	Acute psychological stress-induced water intoxication. International Journal of Psychiatry in Clinical Practice, 2005, 9, 142-144.	2.4	2
330	Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice. Archives of Disease in Childhood, 2004, 89, 877-880.	1.9	30
331	Prophylaxis of acute chemotherapy-induced nausea and vomiting in children with cancer: What is the evidence?. Pediatric Blood and Cancer, 2004, 43, 651-658.	1.5	22
332	Temperature modulation of DHPLC analysis for detection of coexisting constitutional and mosaic sequence variants in TSC2. Journal of Proteomics, 2002, 51, 161-164.	2.4	15
333	The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management. Expert Review of Anticancer Therapy, 0, , 1-9.	2.4	1